Via Transportation Inc (VIA) Stock News

MicroVision announced the commercial production launch of MOVIA Pro, its next-generation short-range lidar sensor with integrated onboard perception and multi-echo sensing capabilities. The sensor is designed for industrial, infrastructure, defense, and autonomous applications, featuring edge AI processing, open software framework, and flexible connectivity. The company's Orlando-based production facility is manufacturing the sensor to meet customer demand as the industry transitions toward solid-state lidar architectures.

IQVIA Holdings is expected to report Q3 2026 earnings on October 27, with consensus estimates of $3.24 EPS (up 8% YoY) and $4.36B in revenues (up 6.4% YoY). However, recent analyst revisions have turned slightly bearish, resulting in a negative Earnings ESP of -0.09%, making it difficult to predict an earnings beat despite the company's strong historical track record of beating estimates in the last four quarters.

argenx announced that Phase 3 ALKIVIA study results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis will be presented as a late-breaking oral presentation at ACR Convergence 2026. The study met its primary endpoint, showing a 15.4-point greater improvement in Total Improvement Score versus placebo at Week 52 in the combined IMNM and DM population, with improvements observed as early as Week 4 and sustained through 52 weeks. The drug was well-tolerated with a consistent safety profile.

Veeva Systems expanded its partnership with IQVIA, with IQVIA selecting additional Veeva clinical operations applications as enterprise standards for clinical development studies. The agreement covers CTMS, eTMF, Study Startup, and Site Connect tools, building on their previous EDC partnership. This expansion is expected to strengthen Veeva's presence in clinical research, improve trial efficiency, and create cross-selling opportunities, though financial terms and deployment timelines were not disclosed.

FORVIA HELLA has secured two major series orders for highly integrated EnergyCore solutions, including a first-of-its-kind 3-in-1 high-voltage battery management system and a 48-volt PowerPack. The combined order volume is in the mid-three-digit million-euro range, with series production starting in December 2027 and spring 2028. These orders validate FORVIA Group's IGNITE strategy to position the company as a leading provider of integrated battery and power electronics system solutions.

DBV Technologies submitted a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch, a non-invasive epicutaneous immunotherapy treatment for peanut allergies in children aged 4-7 years. The submission is supported by positive results from the VITESSE Phase 3 clinical trial involving 654 children, the largest immunotherapy trial for this population. DBV has requested Priority Review status.

DBV Technologies announced the submission of a Biologics License Application (BLA) to the FDA for its VIASKIN® Peanut patch, designed to treat peanut allergies in children aged 4-7 years. The application is based on positive results from the Phase 3 VITESSE clinical trial, the largest immunotherapy study conducted in this patient population, involving 654 children. DBV has requested priority review of the BLA.

IQVIA (IQV) has surged 60.1% over six months, driven by 6% organic growth in Q2 2026, with R&DS bookings up 19.3% and a $34.2 billion backlog. The company's rapid AI adoption—294 agents deployed across 90 use cases with 19 of top 20 pharma companies adopting solutions—is strengthening its competitive position and supporting sustained growth.

Investors in Via Transportation (NYSE: VIA) have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit related to the company's September 2025 IPO. The complaint alleges that the registration statement and prospectus contained materially misleading statements and omitted required disclosures. At the time of the IPO, Via was allegedly adding customers faster than they generated revenue, causing a decline in ARR per customer, and faced regulatory challenges in Germany. Via's stock has declined approximately 70% from its offering price to $14.52.

Class action lawsuits have been filed against four publicly-traded companies alleging securities fraud. Erasca faces allegations regarding misleading preclinical data comparisons; Via Transportation failed to disclose declining ARR and regulatory issues; Embecta misrepresented guidance and segment weakness; and Zillow mischaracterized its Redfin agreement and downplayed antitrust risks. Investors have until mid-August 2026 to file lead plaintiff motions.

Rosen Law Firm announces securities class action lawsuits against Via Transportation, Inc., GPGI, Inc. (formerly CompoSecure), and ADMA Biologics, Inc. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the August 10, 2026 deadline. Via's lawsuit alleges the IPO offering documents were false and misleading regarding declining revenue and growth obstacles, resulting in a 70% stock decline.

IQVIA CEO Ari Bousbib sold approximately 106,000 shares worth $26.1 million through an exercise-and-sell of expiring stock appreciation rights. The sale follows a strong Q2 earnings report with record clinical bookings of $3.15 billion and 8.7% revenue growth. Bousbib maintains a substantial 1.4 million share position, indicating the sale was routine calendar management rather than a bearish signal.

Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Via Transportation, Inc. for alleged securities fraud related to its September 2025 IPO. The lawsuit claims the IPO offering documents were materially false and misleading, omitting that the company was adding customers faster than they generated revenue and facing regulatory headwinds in Germany. Via Transportation stock has declined approximately 70% below its $46 IPO price following successive negative earnings announcements in November 2025, February 2026, and May 2026.

FORVIA announced its H1 2026 financial results, reporting margin expansion and strong net cash flow generation. The company confirmed its full-year guidance, demonstrating progress on its IGNITE strategic roadmap. The financial report has been filed with French financial authorities and is available on the company's investor relations website.

FORVIA announced its H1 2026 financial results on July 31, 2026, reporting margin expansion and strong net cash flow generation. The company confirmed its full-year guidance, demonstrating progress on its IGNITE strategic roadmap. The financial report has been filed with the French financial authority and is available on the company's investor relations website.

ClaimsFiler reminds investors with losses exceeding $100,000 that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Via Transportation. The lawsuit alleges that Via's IPO registration statement and prospectus contained materially misleading statements and omitted material information. The complaint claims that at the time of the IPO, Via was adding customers faster than they were generating revenue, resulting in declining ARR per customer, and faced regulatory obstacles in Germany. Via's stock has declined approximately 70% from its offering price to $14.52.

Rosen Law Firm is notifying investors about securities class action lawsuits, with an August 10, 2026 deadline to serve as lead plaintiff. The main case involves Via Transportation, Inc., where the firm alleges the IPO offering documents were false and misleading regarding the company's declining revenue growth and inability to expand in Germany, resulting in a ~70% stock price decline.

Holzer & Holzer, LLC has filed shareholder class action lawsuits against Via Transportation and Embecta Corp., alleging false and misleading statements in their IPO registration statements and securities disclosures. The firm is also investigating ADTRAN Holdings for potential federal securities law violations. Investors who suffered losses are encouraged to contact the firm.

Rosen Law Firm is encouraging investors who purchased Via Transportation, Inc. (NYSE: VIA) stock during its IPO to join a securities class action lawsuit. The lawsuit alleges that Via's IPO offering documents were false and misleading, omitting information about declining Platform Annual Run-Rate Revenue and inability to grow in Germany. Via's stock has declined approximately 70% from its IPO price to $14.52. The lead plaintiff deadline is August 10, 2026.

A class action lawsuit has been filed against Via Transportation, Inc. (NYSE:VIA) alleging that its September 2025 IPO offering documents were false and misleading. The complaint claims Via omitted material facts about declining growth and obstacles in Germany. Following a March 2026 research report questioning Via's business model and revenue recognition practices, the stock fell 59.7% from its $46 IPO price. Investors have until August 10, 2026 to apply as lead plaintiffs.

A class action lawsuit has been filed against Via Transportation, Inc. (NYSE: VIA) alleging that the company made materially false statements during its September 2025 IPO and failed to disclose declining revenue per customer and regulatory headwinds in Germany. The stock has fallen nearly 70% from its $46 IPO price to $14.12 as of May 2026. Investors have until August 10, 2026 to file a lead plaintiff motion.

The Schall Law Firm has filed a class action lawsuit against Via Transportation, Inc. (NYSE: VIA) for securities fraud related to its September 2025 IPO. The company allegedly made false statements about its business growth and 'land and expand' strategy, particularly regarding German operations, while concealing declining Annual Run-Rate Revenue (ARR) and regulatory pressures in Germany that were revealed on May 12, 2026.

Rosen Law Firm is urging investors who purchased Via Transportation, Inc. (NYSE: VIA) stock during its IPO to join a securities class action lawsuit before the August 10, 2026 deadline. The lawsuit alleges that Via's IPO offering documents were false and misleading, omitting information about declining Platform Annual Run-Rate Revenue and growth obstacles in Germany. Via's stock has declined approximately 70% from its IPO price to $14.52.

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against four publicly-traded companies: BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. The complaints allege that defendants made false or misleading statements regarding their business operations, financial performance, and prospects. Investors have until August 7-10, 2026 to file lead plaintiff motions.

The Schall Law Firm has filed a class action lawsuit against Via Transportation, Inc. (NYSE: VIA) for securities fraud related to its September 2025 IPO. The company allegedly made false statements about its business growth and 'land and expand' strategy, particularly regarding German operations, while concealing declining Annual Run-Rate Revenue (ARR) and regulatory pressures in Germany that were revealed on May 12, 2026.

Rosen Law Firm is urging investors who purchased Via Transportation, Inc. (NYSE: VIA) stock during its IPO to join a securities class action lawsuit before the August 10, 2026 deadline. The lawsuit alleges that Via's IPO offering documents were false and misleading, omitting information about declining Platform Annual Run-Rate Revenue and growth obstacles in Germany. Via's stock has declined approximately 70% from its IPO price to $14.52.

Rosen Law Firm is urging investors who purchased Via Transportation, Inc. (NYSE: VIA) stock during its IPO to join a securities class action lawsuit before the August 10, 2026 deadline. The lawsuit alleges that Via's IPO offering documents were false and misleading, omitting information about declining Platform Annual Run-Rate Revenue and growth obstacles in Germany. Via's stock has declined approximately 70% from its IPO price to $14.52.

Robbins Geller announces a class action lawsuit against Via Transportation (NYSE: VIA) for allegedly making false and misleading statements in its September 2025 IPO prospectus. The lawsuit claims Via Transportation omitted material facts about declining revenue per customer and regulatory issues in Germany. The stock has fallen approximately 70% below its $46 IPO price following subsequent earnings disclosures. Investors with substantial losses have until August 10, 2026 to seek lead plaintiff status.

A securities class action lawsuit has been filed against Via Transportation, Inc. (NYSE: VIA) alleging that the company's IPO offering documents were false and misleading. The complaint claims Via omitted material facts about declining Platform Annual Run-Rate Revenue and inability to grow in Germany. Following the disclosure of these facts, Via's stock price declined approximately 70% from its IPO price to $14.52. Investors who purchased Via common stock in connection with the IPO may be eligible for compensation. The deadline to move the court to serve as lead plaintiff is August 10, 2026.

Rosen Law Firm is urging investors who purchased Via Transportation, Inc. (NYSE: VIA) stock during its IPO to join a securities class action lawsuit before the August 10, 2026 deadline. The lawsuit alleges that Via's IPO offering documents were false and misleading, omitting information about declining Platform Annual Run-Rate Revenue and growth obstacles in Germany. Via's stock has declined approximately 70% from its IPO price to $14.52.